ZHANG Research Team
Nano Biomedicine Lab



Introduction - NBM

   The research group has conducted research on the problems faced by accurate imaging diagnosis and efficient treatment of clinical cancer. Guided by the actual needs of clinical cancer, the group has proposed a new strategy for regulating the function of cell membrane proteins in vivo, has constructed a variety of nanomaterials precise delivery systems, explored the mechanism of nanoparticles in vivo, and realized the clinical translation application of frontier basic research. Biomaterial synthesis, nano sample preparation, cell culture and molecular biology experiments involved in the project can be completed in the biomaterial nanomedicine lab established by Dr. Zhang (about 150 ㎡ in total).


—————————————————————————————————————————————————————

About NBM
PI
AD0I99r2BRACGAAgpbX32AUosIKYbDDtAjjnAQ


Dr. ZHANG Lu

Assistant Professor   Doctoral supervisor

Department of Biomedical Engineering of SUSTech

Email: zhanglu@sustech.edu.cn

Pers. web: http://www.zhanglu_nbm_en.com

Dr. Zhang obtained his Ph.D. at Sun Yat-sen University in 2016 and became a post-doctoral fellow at University of California Davis from 2016 to 2021. As the first and corresponding author, Dr. Zhang has published 11 peer-reviewed papers in the famous international journals, such as Nat. Nanotechnol., Nano Lett., ACS Nano, Adv. Funct. Mater., etc. and has been authorized two international patents. He leads to successfully carry out three clinical translational projects of polyamine acid-based nanomedicines, one of which on targeted therapy of bladder cancer has been approved for phase I clinical trial in the United States.

Five Selected Publications
文章附图

Human epidermal growth factor receptor 2 (HER2) is overexpressed in >20% of breast cancers. Dimerization of HER2 receptors leads to the activation of downstream signals enabling the proliferation...

文章附图

To be clinically efficacious, nanotherapeutic drugs need to reach disease tissues reliably and cause limited side effects to normal organs and tissues. Here, we report a proof-of-concept study...

文章附图

Sophisticated self-assembly may endow materials with a variety of unique functions that are highly desirable for therapeutic nanoplatform. Herein, we report the coassembly of two structurally...

文章附图

Immune checkpoint blockade (ICB) therapy has revolutionized clinical oncology. However, the efficacy of ICB therapy is limited by the ineffective infiltration of T effector (Teff) cells to tumors...

文章附图

Real-time tracking of the dynamics change of self-assembled nanostructures in physiological environments is crucial to improving their delivery efficiency and therapeutic effects. However, such...

Latest News

2022

05-13

Dr. Zhang was invited to participate in the Tsinghua SIGS Health Engineering Forum and made a report    On May 13, Dr. Zhang was invited to participate in the Tsinghua SIGS Health Engineering Forum...

2022

04-23

Dr. Zhang hosted the branch venue of 10th WACBE World Congress on Bioengineering (online) From April 22 to 23, 2022, the two-day 10th WACBE World Congress on Bioengineering was held by the World ...

2022

04-12

Sponsored by the Chinese Society of Biomedical Engineering, and organized by Guangdong Academy of Medical Sciences, Southern University of Science and Technology, Shenzhen University of Technology...

2021

11-11

On November 11th, Professor Zhang Lu was invited to attend the annual meeting of Molecular Imaging Branch of Guangdong Precision Medicine Application Association and the second South China...

2021

10-01

 From October 1st to October 2nd, Professor Zhang Lu was invited by Professor Zhang Bin of Sun Yat-sen University to attend an academic seminar at Sun Yat-sen University, and negotiated project...
CONTACT US
QQ:1013829160
WeChat:15174901408
Email:suoy@mail.sustech.edu.cn